Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ43N1)

• Drug Name: N-adamantyl-N'-cyclohexylurea Drug Info
• Synonyms: CHEMBL242255; N-1-adamantyl-N'-cyclohexylurea; AC1NMPQQ; Urea-based compound, 13; ChemDiv3_000178; Oprea1_419513; 1-adamantyl-3-cyclohexylurea; MLS000719875; SCHEMBL653168; BDBM25732; MolPort-003-713-177; HMS2616F12; HMS1473I02; 3-adamantan-1-yl-1-cyclohexylurea; 1-(1-adamantyl)-3-cyclohexylurea; ZINC3895072; AKOS001483388; MCULE-6291906995; 1-(Adamantane-1-yl)-3-cyclohexylurea; IDI1_019496; N-adamantanyl(cyclohexylamino)carboxamide; NCGC00177652-01; SMR000304404; EU-0000129; ST51030996; US8815951, 192; SR-01000389488

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 5029871
  TTD Drug ID: DMZ43N1

Molecule-Related Drug Atlas

Drug(s) Targeting Soluble epoxide hydrolase (EPHX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AR9281	DMJHA6Q	Hypertension	BA00-BA04	Phase 2	[1]
GSK2256294	DM7FN12	Chronic obstructive pulmonary disease	CA22	Phase 1	[2]
13-n-Heptanamidotridec-8(Z)-enoic acid	DM0LGWJ	Discovery agent	N.A.	Investigative	[3]
N-(naphthalen-1-yl)benzo[d]isoxazol-3-amine	DM2CBNG	Discovery agent	N.A.	Investigative	[4]
1-adamantan-1-yl-3-(6-propyloxyhexyl)urea	DMO1L3I	Discovery agent	N.A.	Investigative	[5]
13-(N-Methyl-n-heptnamido)tridec-8(Z)-enoic acid	DM689TH	Discovery agent	N.A.	Investigative	[3]
N-(3,3-Diphenyl-propyl)-isonicotinamide	DMOXR4K	Discovery agent	N.A.	Investigative	[6]
1-Adamantan-1-yl-3-(3-hydroxy-phenyl)-urea	DM8SEJP	Discovery agent	N.A.	Investigative	[7]
1-Cyclohexyl-3-(1-propionylpiperidin-4-yl)urea	DMAZYCD	Discovery agent	N.A.	Investigative	[8]
1-(4-(3-morpholinopropoxy)phenyl)-3-phenylurea	DMYIK9W	Discovery agent	N.A.	Investigative	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Soluble epoxide hydrolase (EPHX2)	TT7WVHI	HYES_HUMAN	Inhibitor	[1]

References

• [1] Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem. 2007 Aug 9;50(16):3825-40.
• [2] In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31.
• [3] 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates containing epoxide bioisosteres: influence upon vascular relaxation and soluble epoxi... J Med Chem. 2009 Aug 27;52(16):5069-75.
• [4] A strategy of employing aminoheterocycles as amide mimics to identify novel, potent and bioavailable soluble epoxide hydrolase inhibitors. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5716-21.
• [5] 1,3-disubstituted ureas functionalized with ether groups are potent inhibitors of the soluble epoxide hydrolase with improved pharmacokinetic prope... J Med Chem. 2007 Oct 18;50(21):5217-26.
• [6] Structure-based optimization of arylamides as inhibitors of soluble epoxide hydrolase. J Med Chem. 2009 Oct 8;52(19):5880-95.
• [7] Salicylate-urea-based soluble epoxide hydrolase inhibitors with high metabolic and chemical stabilities. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1784-9.
• [8] 1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, a... J Med Chem. 2010 Oct 14;53(19):7067-75.
• [9] Unsymmetrical non-adamantyl N,N'-diaryl urea and amide inhibitors of soluble expoxide hydrolase. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4259-63.